2019 Preliminary Program

Working titles/topics shown. Final titles and speakers will follow

Day 1 – Saturday, April 27, 2019


Project LEAD® Workshop: Awakening Dormant Tumor Cells

This LEAD® Grads-only session will highlight the relationship between chronic inflammation and the metastatic recurrence of breast cancer. In particular, this session will explore the role of neutrophils, a specific type of immune cell, in the awakening of dormant cancer cells. Neutrophils can form neutrophil extracellular traps (NETs) as part of the body's reaction to inflammation. By targeting NETs, we may be able to prevent cancer recurrence.

Confirmed Speakers:

  • Mikala Egeblad, PhD, Associate Professor, Cold Spring Harbor Laboratory


Plenary Session (1): The Breast Cancer Treatment Landscape – What’s on the Horizon?

Over the past decade, there have been enormous changes in the thoughts around how to effectively treat breast cancer. In addition, the tumor microenvironment is increasingly recognized to play a significant role in tumorigenesis. This session will discuss some of the biggest changes in our thinking about how to treat breast cancer, including novel immunotherapy strategies to cell-cycle checkpoint inhibitors and more.

Confirmed Speakers:

  • Stephanie Goff, MD, Associate Research Physician, Surgery Branch, Center for Cancer Research, National Cancer Institute
  • Nicholas P. McAndrew, MD, MSCE, Clinical Instructor, Division of Hematology/Oncology, UCLA David Geffen School of Medicine
  • Sasha Stanton, MD, PhD, Assistant Professor, University of Washington Oncology, Cancer Vaccine Institute


Finding Your Niche: A Welcome Orientation for New Leaders

Led by NBCC board members and advocates, this session will help first-time attendees navigate the conference program and get the very most out of the many opportunities presented at the conference. Special attention will be given to key plenary sessions, must-attend workshops, lobby day and special events.


Days 2 and 3 – Sunday, April 28, 2019 and Monday April 29, 2019


Plenary Sessions


Plenary Session (2): Conflicts of Interest and their Impact on Progress Toward Ending Breast Cancer

This panel will discuss what constitutes a conflict of interest and how pervasive conflicts are in the field of breast cancer research. It will also explore the factors and perverse incentives behind these conflicts and their impact on efforts to end breast cancer. The key question to be addressed is how advocates can play a role in changing the system. 

Confirmed Speakers:

  • Matthew McCoy, PhD, Assistant Professor, Department of Medical Ethics and Health Policy, Perelman School of Medicine, University of Pennsylvania 
  • Aaron P. Mitchell, MD, MPH, Medical Oncologist, Memorial Sloan Kettering Cancer Center (MSK); Assistant Attending, Department of Epidemiology and Biostatistics, MSK


Plenary (3): Nine Years into the ARTEMIS Project® What Have We Accomplished and Where Do We Go Next? 

The Artemis Project® is a collaboration of researchers, advocates, and other key stakeholders who set priorities and design and implement research plans that focus on two areas: prevention of breast cancer and prevention of metastasis. Learn about what has been accomplished under this initiative and what still needs to be done.

Confirmed Speakers:

  • Keith Knutson, PhD, Professor of Immunology, Department of Immunology; Director, Mayo Clinic Florida Discovery and Translation Labs, Cancer Research Program; Director, Mayo Clinic Cancer Center Immunology and Immunotherapy Program
  • Cyrus Ghajar, PhD, Director, Laboratory for the Study of Metastatic Microenvironments (LSM2), Fred Hutchinson Cancer Research Center
  • Alana Welm, PhD, Associate Professor in the Department of Oncological Sciences at the University of Utah, an Investigator at the Huntsman Cancer Institute, and Co-Leader of the Cell Response and Regulation Program at HCI


Plenary (4): Advocates in Science – Advocacy Organizations Leading the Charge

The session will feature speakers from other advocacy communities, who will share how their organizations are taking on collaborative and leadership roles to help move their research agendas.

Confirmed Speakers:

  • Mark Harrington, Executive Director, Treatment Action Group
  • Norman Scherzer, Executive Director, The Life Raft Group
  • Elizabeth Frank, MA, Patient Advocate, Breast Cancer Advocacy Group, Dana Farber Cancer Institute


Plenary (5): Advocacy in the New Political Climate

With a new Congress in 2019, it is more important than ever that NBCC advocates take to the Hill to explain our agenda and push for support. Learn about the current mix of Senators and Representatives, and strategies/techniques for working with freshman members of congress. 


Lobby Day Briefing

When advocates visit Capitol Hill in large numbers, at the same time and around the same policy issue, they have a better chance of their advocacy being heard. This briefing session will provide essential tips and resources for the day ahead. Whether you’re a Lobby Day veteran or it’s your first year, this session will be vital to prepare participants for a successful experience.

Confirmed Speakers:

  • Fran Visco, JD, President, NBCC
  • Jennifer Berzok 


Workshops (Partial List)


Disparities in Breast Cancer – Ending Breast Cancer Requires Eliminating Known Inequalities in Access to Care

Confirmed Speakers:

  • Otis W. Brawley, MD, Bloomberg Distinguished Professor, Johns Hopkins Bloomberg School of Public Health and the Johns Hopkins Kimmel Cancer Center


Metastatic Breast Cancer and the Tumor Microenvironment

Confirmed Speakers:

  • Cyrus Ghajar, PhD, Director, Laboratory for the Study of Metastatic Microenvironments (LSM2), Fred Hutchinson Cancer Research Center

The Science of Breast Cancer Vaccines

Confirmed Speakers:

  • H. Kim Lyerly, MD, George Barth Geller Professor, Professor of Surgery, Immunology, and Pathology, Duke University School of Medicine


Reading Beyond the Hype -  Examining News Media and Scientific Literature Claims Regarding Cancer Treatments

Confirmed Speakers:

  • Gary Schwitzer, Publisher and Founder, Health News Review


Clinical Trial Design and Outcomes

Confirmed Speakers:

  • Lynn Howie, MD, Oncologist, formerly a Medical Officer in the Division of Oncology Products, Center for Drug Evaluation and Research at the U.S. Food and Drug Administration

Value and Transparency in Cancer Drug Development

Confirmed Speakers:

  • Aaron N. Winn, PhD, Assistant Professor, Pharmacy Administration, Department of Clinical Sciences, Medical College of Wisconsin

Informed Consent in Clinical Research

Confirmed Speakers:

  • Pat Haugen, NBCC Board of Directors Alternate, Minnesota Breast Cancer Coalition


Advocacy Planning and Survival Skills


Day 4 Program – Tuesday, April 30, 2019


Annual Lobby Day